Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, has entered into a three-year strategic research partnership with Vertex Pharmaceuticals (VRTX). This collaboration aims to leverage Orna's innovative LNP delivery solutions to advance Vertex's development of next-generation gene editing therapies targeting Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia.
Under the terms of the agreement, Orna will receive an initial payment of $65 million, which includes a convertible note investment. Additionally, Orna stands to earn up to $635 million, contingent upon meeting specific pre-clinical, research, development, regulatory, and commercial milestones for products related to SCD/TDT. Furthermore, Orna may qualify for up to $365 million in extra option fees and milestones for each of up to ten additional products should Vertex choose to exercise options in other indications. The three-year research collaboration will be funded by Vertex.
The material has been provided by InstaForex Company - www.instaforex.com
Under the terms of the agreement, Orna will receive an initial payment of $65 million, which includes a convertible note investment. Additionally, Orna stands to earn up to $635 million, contingent upon meeting specific pre-clinical, research, development, regulatory, and commercial milestones for products related to SCD/TDT. Furthermore, Orna may qualify for up to $365 million in extra option fees and milestones for each of up to ten additional products should Vertex choose to exercise options in other indications. The three-year research collaboration will be funded by Vertex.
The material has been provided by InstaForex Company - www.instaforex.com